Sarepta Therapeutics (NASDAQ:SRPT) Announces Earnings Results

Sarepta Therapeutics (NASDAQ:SRPT) posted its earnings results on Wednesday. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18, FiscalAI reports. The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.90% and a negative net margin of 2.94%.The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.42) earnings per share.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• $748 million in cash and investments; Sarepta reported GAAP and non‑GAAP profitability and positive operating cash flow excluding planned Arrowhead payments, and reaffirmed full‑year revenue guidance of $1.2 billion–$1.4 billion.
• Commercial execution for ELEVIDYS is stabilizing with expanded field reach, a larger contract sales force, new educational resources, and early “green shoots” of demand; ELEVIDYS generated $102 million in Q1 product revenue.
• SiRNA portfolio momentum: encouraging early data for SRP‑1001 (FSHD) and SRP‑1003 (DM1), on‑track Huntington’s first dosing, and multiple upcoming readouts in H2‑2026 that Sarepta describes as potentially “best‑in‑class.”
• Regulatory progress on the PMO franchise — Sarepta submitted sNDAs to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval and expects a standard review timeline with a PDUFA roughly around February next year.
• Near‑term demand and growth remain uncertain because of an information gap around ELEVIDYS safety (ALI risk), the need for Cohort 8 sirolimus data to address non‑ambulatory use, long patient decision cycles (~6 months from enrollment to infusion), and recent cash outflows tied to Arrowhead payments that reduced the quarter‑end cash balance sequentially.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $0.08 during trading on Friday, reaching $20.72. The company’s stock had a trading volume of 2,031,147 shares, compared to its average volume of 2,897,738. The business’s fifty day moving average price is $19.77 and its 200-day moving average price is $20.30. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $44.14. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -21.59, a P/E/G ratio of 0.35 and a beta of 0.26.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wedbush boosted their price target on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 26th. Mizuho raised their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Finally, Oppenheimer reissued an “outperform” rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Nine analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.71.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Inceptionr LLC purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth approximately $346,000. Integrated Wealth Concepts LLC purchased a new position in Sarepta Therapeutics in the 4th quarter valued at $335,000. Van ECK Associates Corp increased its stake in Sarepta Therapeutics by 23.6% in the 4th quarter. Van ECK Associates Corp now owns 12,284 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 2,347 shares during the period. Evolve Private Wealth LLC purchased a new position in Sarepta Therapeutics during the 4th quarter worth $259,000. Finally, Deutsche Bank AG raised its position in Sarepta Therapeutics by 25.1% during the 4th quarter. Deutsche Bank AG now owns 11,990 shares of the biotechnology company’s stock worth $258,000 after buying an additional 2,404 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Q1 results materially beat expectations — EPS of $3.16 and revenue of $730.8M topped consensus by wide margins, and management reiterated its full‑year product revenue outlook and emphasized progress on stabilizing the business. Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
• Positive Sentiment: Management commentary and slides highlighted priorities (stabilize business, restore growth, advance the pipeline) and the CEO expressed confidence in a return to growth — a constructive signal for longer‑term investors if execution continues. Sarepta (SRPT) Q1 2026 Earnings Transcript
• Neutral Sentiment: Analyst reaction is mixed but muted: J.P. Morgan reaffirmed a Hold (neutral) view, reflecting balanced upside from near‑term recovery versus execution and regulatory risk. Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
• Neutral Sentiment: Full earnings call transcript and slide deck are available for diligence — useful for investors wanting detail on unit economics, pricing, and pipeline timelines. Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Elevidys demand is down materially and investors cited a “reality check” after regulators tightened scrutiny — the drop in uptake directly pressures near‑term revenue and growth assumptions. Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check.
• Negative Sentiment: After‑hours selling accelerated when headlines highlighted the drop in Elevidys demand; short‑term liquidity and sentiment pressures likely amplified the intraday decline. SRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growth
• Negative Sentiment: Some sell‑side skepticism persists: Citi reiterated a Sell and $13 price target citing safety/regulatory overhangs — a reminder downside remains if Elevidys trends continue or regulatory actions intensify. Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.